The HealthTech For Care endowment fund, which aims to promote access to care for patients, has chosen to open the 5th edition of HealthTech Innovation Days (HTID®) to early-stage European companies. This decision was taken in conjunction with its sponsors from the healthcare ecosystem: leading pharmaceutical companies, industry players, specialist consultancies and investors in healthcare technologies, and institutional partners, as well as its supporters: European clusters and patient associations.
The macro-economic and financial context in Europe for the HealthTech sector remains uncertain, with funding for companies in the ecosystem plummeting worldwide from €55 billion in 2021 to €30 billion in 2022.
While innovation in healthcare remains dynamic, early-stage HealthTech companies are at risk of not receiving the support they need to develop, whether in the form of funding and/or partnerships. This could delay or even halt the development of solutions for patients. To encourage these developments, HTID's participation criteria are evolving to welcome companies at the proof-of-concept stage whose:
> Biotechs developing a treatment currently undergoing in-vivo evaluation, close to applying to regulatory agencies for entry into the clinic.
> Medtechs with a prototype in the patient testing phase.
> Innovative services companies developing innovative products and services for players in the healthcare sector.
> Digital Health with a solution under development with partners such as hospitals, pharmaceutical or industrial companies.
Maryvonne Hiance, President of HealthTech For Care says: "We have become aware of the difficulty of financing companies in Europe. As a public-interest endowment fund, we want to promote access to healthcare for all, and support all innovative companies, whether early-stage or more mature, so that their solutions are available as quickly as possible for the benefit of patients. We hope that this approach will support the dynamic of innovation for the entire healthcare ecosystem in Europe."
HealthTech For Care is supported by its founder France Biotech and the network of French healthcare clusters: Atlanpole biotherapies, BioValley France, EuroBioMed, LyonBioPole, Medicen and the clubster NHL. The endowment fund is also supported by numerous European players: Asebio, BioAlps, BIO Deutschland, BIA, BioWin, CEBR, Federchimica Assobiotec, flanders.bio, HollandBIO, IREFI, Medvia, MedTech Europe, Swiss Biotech, and Technion France.
Registration link for HealthTech early-stage companies:
The HealthTech Innovation Days (HTID®) are held under the High Patronage of Mr Emmanuel MACRON, President of the French Republic, with the participation of the European Commission and the European Investment Bank (EIB). HTID® provides a forum for promising European life sciences companies to accelerate their growth and bring their solutions to patients faster.
It combines :
- One-to-one meetings between innovative European healthcare companies, investors and industrial and pharmaceutical companies,
- Pitch sessions in front of a panel of experts for 25 innovative European healthcare companies selected by European clusters and associations,
- Conferences and round tables led by international opinion leaders.